| Product Code: ETC7181348 | Publication Date: Sep 2024 | Updated Date: Nov 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Shubham Padhi | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
Imports of non-alcoholic steatohepatitis (NASH) biomarkers to Fiji in 2024 were primarily sourced from New Zealand, USA, Australia, India, and Taiwan. Despite a notable negative compound annual growth rate (CAGR) of -57.08% from 2020-2024 and a further decline in growth rate of -57.1% from 2023-2024, the market remains concentrated, as indicated by the high Herfindahl-Hirschman Index (HHI). This data suggests a challenging landscape for NASH biomarker imports to Fiji, with potential implications for market dynamics and supplier relationships.

1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Fiji Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Overview |
3.1 Fiji Country Macro Economic Indicators |
3.2 Fiji Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenues & Volume, 2021 & 2031F |
3.3 Fiji Non-alcoholic Steatohepatitis (NASH) Biomarkers Market - Industry Life Cycle |
3.4 Fiji Non-alcoholic Steatohepatitis (NASH) Biomarkers Market - Porter's Five Forces |
3.5 Fiji Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenues & Volume Share, By Biomarker Type, 2021 & 2031F |
3.6 Fiji Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 Fiji Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of non-alcoholic steatohepatitis (NASH) in Fiji |
4.2.2 Growing awareness about the importance of early diagnosis and monitoring of NASH |
4.2.3 Technological advancements leading to the development of more accurate biomarkers for NASH detection |
4.3 Market Restraints |
4.3.1 Limited healthcare infrastructure in Fiji for NASH diagnosis and treatment |
4.3.2 Lack of skilled healthcare professionals specializing in NASH management |
4.3.3 High cost associated with NASH biomarker tests and monitoring |
5 Fiji Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Trends |
6 Fiji Non-alcoholic Steatohepatitis (NASH) Biomarkers Market, By Types |
6.1 Fiji Non-alcoholic Steatohepatitis (NASH) Biomarkers Market, By Biomarker Type |
6.1.1 Overview and Analysis |
6.1.2 Fiji Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenues & Volume, By Biomarker Type, 2021- 2031F |
6.1.3 Fiji Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenues & Volume, By Serum Biomarkers, 2021- 2031F |
6.1.4 Fiji Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenues & Volume, By Biomarker Panels, 2021- 2031F |
6.1.5 Fiji Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenues & Volume, By Fibrosis Biomarkers, 2021- 2031F |
6.1.6 Fiji Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenues & Volume, By Imaging Biomarkers, 2021- 2031F |
6.1.7 Fiji Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Fiji Non-alcoholic Steatohepatitis (NASH) Biomarkers Market, By End User |
6.2.1 Overview and Analysis |
6.2.2 Fiji Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.2.3 Fiji Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenues & Volume, By Diagnostic Centers, 2021- 2031F |
6.2.4 Fiji Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenues & Volume, By Others, 2021- 2031F |
7 Fiji Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Import-Export Trade Statistics |
7.1 Fiji Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Export to Major Countries |
7.2 Fiji Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Imports from Major Countries |
8 Fiji Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Key Performance Indicators |
8.1 Number of NASH screenings conducted annually |
8.2 Adoption rate of new NASH biomarkers in clinical practice |
8.3 Investment in research and development of NASH biomarkers |
8.4 Patient adherence to recommended NASH monitoring protocols |
8.5 Number of partnerships and collaborations aimed at advancing NASH biomarker technology |
9 Fiji Non-alcoholic Steatohepatitis (NASH) Biomarkers Market - Opportunity Assessment |
9.1 Fiji Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Opportunity Assessment, By Biomarker Type, 2021 & 2031F |
9.2 Fiji Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Opportunity Assessment, By End User, 2021 & 2031F |
10 Fiji Non-alcoholic Steatohepatitis (NASH) Biomarkers Market - Competitive Landscape |
10.1 Fiji Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenue Share, By Companies, 2024 |
10.2 Fiji Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |